Despite the magnitude of the Ebola virus disease (EVD) outbreak in West Africa, there is still a fundamental lack of knowledge about the pathophysiology of EVD 1 . In particular, very little is known about human immune responses to Ebola virus 2,3 . Here we evaluate the physiology of the human T cell immune response in EVD patients at the time of admission to the Ebola Treatment Center in Guinea, and longitudinally until discharge or death. Through the use of multiparametric flow cytometry established by the European Mobile Laboratory in the field, we identify an immune signature that is unique in EVD fatalities. Fatal EVD was characterized by a high percentage of CD4 + and CD8 + T cells expressing the inhibitory molecules CTLA-4 and PD-1, which correlated with elevated inflammatory markers and high virus load.
). The levels of CTLA4 were significantly higher in CD8 + T cells from fatal EVD cases compared to survivors (Extended Data Fig. 1d ). CTLA4 plays an important role in inhibiting T cell func tion, an immune homeostasis mechanism to control excessive or per sistent T cell activation 4, 5 . Owing to its regulatory properties, there are licensed therapeutics to either antagonize or enforce CTLA4 function 6, 7 . Thus, we hypothesized that our findings could reflect a pathophysiological mechanism of EVD that might be amenable to therapeutics. However, we had concerns regarding the quality of the material that arrived at our laboratory after days of transport and we therefore established flow cytometry directly in Guinea to further eval uate T cell immunity in EVD. Leftover diagnostic blood samples from 157 EVD patients tested by the EMLab at the Coyah Ebola Treatment Center (ETC) were transferred to our laboratory in Conakry within 24 h after collection (Extended Data Fig. 2a, b ). The median day of admission at the ETC for both fatalities and survivors was day 4 post symptom onset and, thus, outcome was not associated with the time elapsed between onset of disease and admission ( Fig. 1a) .
First, we evaluated the immune status of EVD patients upon their arrival to the ETC. Owing to the limitation to six parameters in our field analyses (Extended Data Fig. 3 ), we focused on the evaluation of individual markers of T cell function. We determined the expres sion levels of HLADR and Ki67 as markers of activated T cells 8 , as well as PD1 and CTLA4, which together are key regulators of T cell homeostasis 5, 9 . The percentage of CD4 + and CD8 + T cells expressing LETTER RESEARCH CTLA4 and PD1 was significantly higher in fatal cases compared with survivors ( Fig. 1b ). Sometimes more than 50% of total CD8 + T cells expressed CTLA4 (Fig. 1c ). Fatal cases also showed higher frequency of Ki67 + CD8 + T cells and HLADR + CD4 + T cells than survivors ( Fig. 1b ).
High expression of both PD1 and CTLA4 has been correlated with functional exhaustion (loss of function) of T cells in chronic inflam matory conditions [9] [10] [11] . However, the role of these molecules during acute infection is less well understood. In previous studies, expres sion of CTLA4 and PD1 in T cells correlated with the extent of pro inflammatory responses against hantavirus and influenza virus among others [12] [13] [14] . Thus, we next evaluated the levels of pro and anti inflammatory cytokines in fatal and nonfatal EVD. In agreement with previous reports 15, 16 , fatal EVD cases had significantly higher levels of serum proinflammatory cytokines (TNF (also known as TNFα) and IL8) ( Fig. 1d ). Moreover, the levels of proinflammatory chemo kines (MIP1α, MIP1β and MCP1) were also significantly upregulated in fatalities ( Fig. 1d ). Levels of antiinflammatory cytokines such as IL10 were also higher in fatalities suggesting the onset of compensatory homeostatic mechanisms in response to excessive inflammation, consistent with expression of T cell inhibitory molecules such as CTLA4 and PD1.
To gain insight into the correlation between CTLA4 expression and the functional status of T cells in patients we performed analyses of T cells from cryopreserved peripheral blood leukocytes, which allowed evaluation of T cell marker coexpression (Extended Data Fig. 4 ). We used coexpression of CD38 and HLADR as well as CD38 and Ki67 to define activated T cells 3, 8, 13 , and coexpression of CTLA4 and PD1 to identify effector T cells that had activated inhibitory mechanisms 13 . Our results indicated robust CD8 + T cell activation in both fatal and nonfatal EVD cases with no statistically significant difference between the two groups. The frequency of activated CD8 + T cells (around 30% of CD38 + HLADR + and 18% of CD38 + Ki67 + ) was similar to that previously reported in acute surviving medevac EVD patients 3 , and to that described in other acute infections 13 and after vaccination 8 . However, the frequency of CD8 + T cells coexpressing PD1 and CTLA4 was significantly higher in fatalities ( Fig. 2a, b ). The results with CD4 + T cells corresponded to those of CD8 + T cells, with no differences in the activation status between fatal and nonfatal EVD, but a higher frequency of cells coexpressed CTLA4 and PD1 in fatal LETTER RESEARCH cases ( Fig. 2c, d ). CTLA4 + T cells in both CD8 + and CD4 + subsets expressed high levels of CD38 and HLADR, suggesting a discrete sub set of effector T cells that have initiated a compensatory homeostatic mechanism ( Fig. 2b, d ).
Whether or not CTLA4 overexpression affects T cellmediated viral clearance is controversial. While some reports have correlated the frequency of CD8 + T cells expressing CTLA4 with poor viral clearance 14 , others do not support this hypothesis 17 . To explore the relationship between CTLA4 and PD1 expression and virus loads during EVD, we analysed whether the percentage of T cells express ing CTLA4, PD1, or both, correlated with the threshold cycle (C t ) values of the EBOV realtime PCR. Fatal EVD cases had signifi cantly lower C t values at the time of admission in agreement with the C t value being a strong predictor of outcome [18] [19] [20] (Extended Data Fig. 2c-e ). The C t value negatively correlated with the percentage of T cells expressing CTLA4 as well as the percentage of CD8 + T cells coexpressing CTLA4 and PD1 ( Fig. 2e and Extended Data Fig. 5a ). However, the percentage of T cells expressing PD1 alone did not correlate with the C t value (Fig. 2f ). In summary, expression of CTLA4 alone and in combination with PD1 correlated with high viraemia.
Acute lymphopenia triggers proliferation of naive T cells with very low expression of CTLA4 and PD1 (ref. 21) . Thus, we reasoned that differences in Ebola virus (EBOV)induced lymphopenia 2 , could be a confounding variable in our study. However, there were no differences in circulating peripheral blood T cells between fatal and nonfatal EVD cases (Extended Data Fig. 5b) . A recent study comparing infection with the Makona versus Mayinga variants of EBOV in nonhuman primates found evidence of initial leukocytosis followed by moder ate lymphopenia with no overall differences between both EBOV variants 22 . Initial leukocytosis in patients infected with the Makona variant of EBOV has been also observed 23, 24 , which indicates the need of longitudinal evaluation of haematological parameters in patients infected with EBOV Makona, an approach that was not possible in our study due to the lack of statistically relevant numbers of fatal cases with longitudinal sampling. 
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To link the observed activation of CD8 + T cells with EBOVspecific responses, we sought to track EBOVspecific CD8 + T cells during infection through the use of HLA class I dextramers. We first per formed in silico analysis of EBOV nucleoproteinderived peptides predicted to bind with high affinity to selected HLA alleles common in West Africa (HLAA*02:01, HLAA*23:01 and HLAB*35:01) 25 and designed dextramers (Extended Data Fig. 6 ). We chose the EBOV nucleoprotein based on previous reports indicating that nucleoprotein drives most of the CD8 + T cell response 26, 27 . Dextramermatching HLA alleles were identified in 26 patients via sequencing of the HLA locus. Six patients had more than one sample for longitudinal evalua tion of EBOVspecific T cell responses. These included two fatal cases (F1 and F2) and four survivors (S2-S5). S3 and S4 were treated with favipiravir, and all the other patients received only supportive therapy. At the time of admission, the differences in the percentage of EBOV specific T cells between fatalities and survivors were not statistically significant (Fig. 3a) . However, differences became evident during later stages of infection. The fatal cases with longitudinal sampling (F1 and F2) showed a high frequency of PD1 + CTLA4 + CD8 + T cells until death, but barely detectable EBOVspecific CD8 + T cells (Fig. 3b, e ). In contrast, an increase in the frequency of EBOVspecific CD8 + T cells was observed in survivors in coincidence with virus clearance and decrease of the PD1 + CTLA4 + CD8 + T cell population ( Fig. 3c-e ).
These findings were substantiated by the kinetics of CTLA4 expression in two EVD patients, one fatality and one survivor, evac uated to Europe, as well as five survivors treated in Coyah, Guinea. Longitudinal analysis of these patients revealed persistent upregula tion of CTLA4 in the fatal case and transient upregulation in survi vors (Extended Data Fig. 7 ). Of note, the increase of EBOVspecific T cells in the surviving patients coincided with contraction rather than expansion of the CD38 + HLADR + subset (Fig. 3e ). Despite the fact that the phenotype of activated T cells (CD38 + HLADR + ) suggests engagement of the T cell receptor (TCR) and not bystander T cell activation 8 , our findings may point to the presence of nonEBOV specific T cells within the CD38 + HLADR + compartment.
The main hypothesis we formulate on the basis of these data is that differences between the T cell response of fatal and surviving EVD patients are centred in the mechanisms that regulate T cell home ostasis. While all patients showed T cell activation irrespective of outcome, it was the expression of the regulatory molecules CTLA4 and PD1 on peripheral blood T cells that marked fatal EVD and cor related with high viraemia, a known predictor of poor outcome 19, 20 . We hypothesize that this upregulation reflects a compensatory mech anism to excess inflammatory stimuli, which is consistent with the concomitant expression of proinflammatory cytokines in fatal cases. LETTER RESEARCH of CTLA4/PD1 and poor outcome: on one hand it is possible that high viraemia triggers overwhelming inflammation thereby causing CTLA4 and PD1 upregulation on T cells, and on the other hand, it is plausible to assume that expression of these molecules inhibits T cell function leading to poor viral clearance. Indeed, both possi bilities have been reported in the literature 13, 28 and their elucidation requires evaluation of CTLA4 function during EVD in adequate infection models. Interestingly, during severe EVD, both PD1 and CTLA4 are upregulated while in other acute human infections such as hantavirus disease and paediatric influenza, only CTLA4, not PD1, was upregulated 13, 14 . These results suggest that different infections trigger specific regulatory mechanisms, the balance of which is vital for optimal T cell function. Robust T cell activation was observed in both fatal and nonfatal EVD cases as reflected by similar levels of discrete CD8 + and CD4 + T cells coexpressing CD38 and HLADR. These results are in agreement with the strong T cell activation observed in surviving US patients 3 and strengthen the notion that EVD is characterized by immune activation. Although limited, our dextramer data suggest that both fatal and nonfatal cases are able to mount EBOVspecific T cell responses. However, while in survivors the PD1 + CTLA4 + CD8 + T cell compartment contracted in con junction with viral clearance, formation of EBOVspecific T cells and recovery, this did not seem to be the case in fatal EVD. One plausible explanation for this finding is that the high expression of CTLA4 observed in activated T cells of fatal cases promotes cell extrinsic inhi bition of EBOVspecific T cells. Tcellextrinsic CTLA4 functions have been demonstrated in vivo and involve different mechanisms such as stripping of T cell costimulatory molecules from antigen presenting cells, stimulation of regulatory T cells and local tryptophan starvation among others 5, 29, 30 . Further functional experiments with adequate in vivo models are needed to explore the role of regulatory T cell molecules during EVD and to test whether their modulation may serve as a putative postexposure therapy against EVD.
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Extended Data Figure 1 | Initial immunophenotyping data from Guéckédou. a, Graph depicting the number of samples tested by the EMLab unit in Guéckédou by function of time since the beginning of the outbreak. The blue square indicates the period in which leftover whole blood samples from the diagnostic activities were shipped to the BSL4 laboratory in Hamburg for initial immunophenotyping. b, Demographic data of the Guéckédou EVD patient cohort. Adults were ≥ 18 years of age and paediatric patients were <18 years of age. c, Comparison of the expression of CTLA4 assessed by median fluorescence intensity ratio (MFIR) in CD4 + and CD8 + T cells of EVD patients (POS, black boxes) and nonEVD controls (NEG, green boxes). MFIR represents the ratio between the CTLA4specific signal divided by the fluorescence minus one (FMO) signal of the same cell population. d, Comparison between CTLA4 MFIR values in CD8 + T cells from fatal (black) versus surviving (blue) EVD cases. In all panels, the ends of the whiskers in the boxand whisker plots represent the 10th and 90th percentile, respectively. Statistical analysis was performed by nonparametric Mann-Whitney test; *P ≤ 0.05; ***P ≤ 0.0001.
Extended Data Figure 2 | Epidemiological data of patients tested by EMLab unit in Coyah. a, b, Demographic data of the Coyah EVD patient cohort. Adults were ≤18 years of age and paediatric patients were <18 years of age. The median age of the 157 patients in the study was 26 years (interquartile range (IQR) 20-38 years). Percentages of males and females were comparable within all groups, with adults accounting for 79% of patients. c, Boxandwhisker plots depicting statistical association between C t values and outcome. The case-fatality ratio (CFR) was 51.6%. Fatalities and survivors were compared via nonparametric Mann-Whitney test; ***P < 0.001. d, Correlation between C t value and age of the patients. The C t value did not correlate with age. However, survivors clustered in a group characterized by C t value higher than 18 and by age less than 40 years (cluster encircled in blue). Statistical significance was tested by nonparametric Spearman correlation analysis. e, C t values correlated negatively with symptom scoring, so that low C t values were associated with severe disease symptoms. Symptom score was calculated as the summation of individual symptoms (bleeding, liver dysfunction, respiratory distress, kidney failure, neurological symptoms and anorexia) from '0' (no symptoms) to '6' (all symptoms present). In the boxandwhisker plot the ends of the whiskers represent the 10th and 90th percentile, respectively. Statistical analysis was performed by nonparametric Mann-Whitney test; ***P ≤ 0.0001.
Extended Data Figure 6 | In silico peptide analysis and dextramer design. a, Selection of peptides consisting of nine amino acid residues corresponding to the EBOV nucleoprotein sequence predicted to bind the indicated HLA alleles. IC 50 values for peptide binding to HLA were predicted by the artificial neural network (ANN) at the Immune Epitope Database and Analysis Resource (IEDB) (http://www.iedb.org). b, Dextramer background was determined by staining of HLAmatched healthy donor peripheral blood leukocyte samples. T cells were gated as indicated in Extended Data Fig. 4 . Plots in the upper row represent staining of a FMO (fluorescent minus one) sample in which the APC channel was left empty. Lower rows show background dextramer staining as indicated. The mean background staining plus minus standard deviation is indicated for each dextramer and the FMO.
